Cellectis (NASDAQ:CLLS) Announces Quarterly Earnings Results

Cellectis (NASDAQ:CLLS) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03), Zacks reports. The firm had revenue of $18.05 million during the quarter, compared to analyst estimates of $5.00 million. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. During the same quarter in the previous year, the business posted ($0.31) EPS.

Cellectis Stock Down 1.7 %

NASDAQ:CLLS traded down $0.03 during trading hours on Wednesday, reaching $1.75. The company’s stock had a trading volume of 123,752 shares, compared to its average volume of 48,823. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.92 and a quick ratio of 1.92. The company has a market cap of $97.27 million, a price-to-earnings ratio of -1.38 and a beta of 3.10. The business’s 50-day moving average is $2.08 and its 200-day moving average is $2.28. Cellectis has a one year low of $1.75 and a one year high of $3.77.

Wall Street Analyst Weigh In

Several research firms recently commented on CLLS. Barclays lowered their target price on Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday. StockNews.com started coverage on shares of Cellectis in a research note on Tuesday. They set a “sell” rating on the stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.